ZNF503-AS2 is a promising therapeutic target and is associated with the immune microenvironment in glioma
Glioma is the most common intracranial malignancy, and the available treatment options are poor. Long noncoding RNAs (lncRNAs) have been reported to be involved in the malignant progression of glioma. The role of ZNF503-AS2 in glioma has not been reported. We screened ZNF503-AS2 with upregulated exp...
Gespeichert in:
| Veröffentlicht in: | PloS one 2024-12, Vol.19 (12), p.e0314618 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | e0314618 |
| container_title | PloS one |
| container_volume | 19 |
| creator | Wu, Yibo Mu, Guangjing Li, Fang Sun, Yanfei Lin, Xiaoying Liu, Xuemeng Zhao, Zhimin Han, Mingzhi Wang, Donghai Huang, Bin Li, Xingang |
| description | Glioma is the most common intracranial malignancy, and the available treatment options are poor. Long noncoding RNAs (lncRNAs) have been reported to be involved in the malignant progression of glioma. The role of ZNF503-AS2 in glioma has not been reported.
We screened ZNF503-AS2 with upregulated expression in glioblastoma (GBM) by analyzing the TCGA, CGGA and GTEx databases. Single sample gene set enrichment analysis (ssGSEA) was used to calculate the enrichment of immune cells and signaling pathways in glioma samples. Single-cell datasets were used to analyze the distribution of ZNF503-AS2. In vitro experiments were used to investigate the biological function of ZNF503-AS2.
ZNF503-AS2 was highly expressed in glioma and was associated with poor prognosis, malignant progression and infiltration of immunosuppressive cells. Single-cell transcriptomic analysis showed that ZNF503-AS2 was mainly expressed in macrophages and tumor cells. Further analysis revealed that immunotherapy may have better efficacy in patients with low ZNF503-AS2 expression. In vitro experiments showed that knockdown of ZNF503-AS2 reduced the proliferation, invasion and migration ability of glioma cells, induced G2/M cell cycle arrest and promoted apoptosis.
ZNF503-AS2 might be a valuable biomarker for predicting the prognosis of glioma patients and a potential target for glioma therapy. |
| doi_str_mv | 10.1371/journal.pone.0314618 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_3135057024</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A818681228</galeid><doaj_id>oai_doaj_org_article_1d360960f596410ba8054d7ddc7b9cff</doaj_id><sourcerecordid>A818681228</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-49f0489d33d62605a9b6000bf7133108fde654208a1420ba26df59fe8fa9857f3</originalsourceid><addsrcrecordid>eNptksFu1DAQhiMEoqXwBggsIVVcdhnHsWOfqlXVQqUKDsCFi-WN7axXib3YSRFvj9NNq11URXIs-5v5Z8Z_UbzFsMSkxp-2YYxedctd8GYJBFcM82fFKRakXLASyPOD_UnxKqUtACWcsZfFCRGsxEzQ08L9-npNgSxW30vkElJoF0PvkvMtGjYmqp0ZB9egQcXWDEh5fU-lFBqnBqPRHzdsJhK5vh-9Qb1rYjD-zsXge-MH5DxqOxd69bp4YVWXzJv5f1b8vL76cfllcfvt883l6nbRUKiGRSUsVFxoQjQrGVAl1gwA1rbGhGDgVhtGqxK4wnldq5JpS4U13CrBaW3JWfF-n3fXhSTnKSVJMKFAayirTNzsCR3UVu6i61X8K4Ny8v4gxFaqmLvujMSaMBAMsgSrcJbjQCtda93Ua9HYSe1iVhvXvdFNbjmq7ijp8Y13G9mGO4kxwxjTqZqPc4YYfo8mDTLPvzFdp7wJ41R4BaIkwCb0w3_o0-3NVKtyB87bkIWbKalcccwZx2XJM7V8gsqfNvkNs6esy-dHAecHARujumGTQpftEXw6Bqs9mJ2QUjT2cRoY5GTdh6rlZF05WzeHvTuc5GPQg1fJP6A76UA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3135057024</pqid></control><display><type>article</type><title>ZNF503-AS2 is a promising therapeutic target and is associated with the immune microenvironment in glioma</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Wu, Yibo ; Mu, Guangjing ; Li, Fang ; Sun, Yanfei ; Lin, Xiaoying ; Liu, Xuemeng ; Zhao, Zhimin ; Han, Mingzhi ; Wang, Donghai ; Huang, Bin ; Li, Xingang</creator><creatorcontrib>Wu, Yibo ; Mu, Guangjing ; Li, Fang ; Sun, Yanfei ; Lin, Xiaoying ; Liu, Xuemeng ; Zhao, Zhimin ; Han, Mingzhi ; Wang, Donghai ; Huang, Bin ; Li, Xingang</creatorcontrib><description>Glioma is the most common intracranial malignancy, and the available treatment options are poor. Long noncoding RNAs (lncRNAs) have been reported to be involved in the malignant progression of glioma. The role of ZNF503-AS2 in glioma has not been reported.
We screened ZNF503-AS2 with upregulated expression in glioblastoma (GBM) by analyzing the TCGA, CGGA and GTEx databases. Single sample gene set enrichment analysis (ssGSEA) was used to calculate the enrichment of immune cells and signaling pathways in glioma samples. Single-cell datasets were used to analyze the distribution of ZNF503-AS2. In vitro experiments were used to investigate the biological function of ZNF503-AS2.
ZNF503-AS2 was highly expressed in glioma and was associated with poor prognosis, malignant progression and infiltration of immunosuppressive cells. Single-cell transcriptomic analysis showed that ZNF503-AS2 was mainly expressed in macrophages and tumor cells. Further analysis revealed that immunotherapy may have better efficacy in patients with low ZNF503-AS2 expression. In vitro experiments showed that knockdown of ZNF503-AS2 reduced the proliferation, invasion and migration ability of glioma cells, induced G2/M cell cycle arrest and promoted apoptosis.
ZNF503-AS2 might be a valuable biomarker for predicting the prognosis of glioma patients and a potential target for glioma therapy.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0314618</identifier><identifier>PMID: 39621695</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Apoptosis ; Biological effects ; Biology and Life Sciences ; Biomarkers ; Biotechnology ; Brain Neoplasms - genetics ; Brain Neoplasms - immunology ; Brain Neoplasms - pathology ; Care and treatment ; Cell cycle ; Cell Line, Tumor ; Cell Movement ; Cell Proliferation ; Complications and side effects ; Development and progression ; Diagnosis ; Drug resistance ; Female ; Flow cytometry ; Gene Expression Regulation, Neoplastic ; Gene set enrichment analysis ; Genes ; Glioblastoma ; Glioma ; Glioma - genetics ; Glioma - immunology ; Glioma - metabolism ; Glioma - pathology ; Glioma cells ; Gliomas ; Growth factors ; Health aspects ; Humans ; Immune system ; Immunotherapy ; Leukocyte migration ; Macrophages ; Male ; Malignancy ; Medical prognosis ; Medical research ; Medicine and Health Sciences ; Medicine, Experimental ; Metastases ; Microenvironments ; MicroRNAs ; Patient outcomes ; Prognosis ; Research and Analysis Methods ; RNA, Long Noncoding - genetics ; Therapeutic targets ; Tissues ; Transcriptomics ; Tumor cells ; Tumor Microenvironment - genetics ; Tumor Microenvironment - immunology ; Tumors</subject><ispartof>PloS one, 2024-12, Vol.19 (12), p.e0314618</ispartof><rights>Copyright: © 2024 Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>COPYRIGHT 2024 Public Library of Science</rights><rights>2024 Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 Wu et al 2024 Wu et al</rights><rights>2024 Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c504t-49f0489d33d62605a9b6000bf7133108fde654208a1420ba26df59fe8fa9857f3</cites><orcidid>0000-0002-0878-0211 ; 0009-0008-6943-3396 ; 0000-0002-0944-7648</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611154/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611154/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79569,79570</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39621695$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Yibo</creatorcontrib><creatorcontrib>Mu, Guangjing</creatorcontrib><creatorcontrib>Li, Fang</creatorcontrib><creatorcontrib>Sun, Yanfei</creatorcontrib><creatorcontrib>Lin, Xiaoying</creatorcontrib><creatorcontrib>Liu, Xuemeng</creatorcontrib><creatorcontrib>Zhao, Zhimin</creatorcontrib><creatorcontrib>Han, Mingzhi</creatorcontrib><creatorcontrib>Wang, Donghai</creatorcontrib><creatorcontrib>Huang, Bin</creatorcontrib><creatorcontrib>Li, Xingang</creatorcontrib><title>ZNF503-AS2 is a promising therapeutic target and is associated with the immune microenvironment in glioma</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Glioma is the most common intracranial malignancy, and the available treatment options are poor. Long noncoding RNAs (lncRNAs) have been reported to be involved in the malignant progression of glioma. The role of ZNF503-AS2 in glioma has not been reported.
We screened ZNF503-AS2 with upregulated expression in glioblastoma (GBM) by analyzing the TCGA, CGGA and GTEx databases. Single sample gene set enrichment analysis (ssGSEA) was used to calculate the enrichment of immune cells and signaling pathways in glioma samples. Single-cell datasets were used to analyze the distribution of ZNF503-AS2. In vitro experiments were used to investigate the biological function of ZNF503-AS2.
ZNF503-AS2 was highly expressed in glioma and was associated with poor prognosis, malignant progression and infiltration of immunosuppressive cells. Single-cell transcriptomic analysis showed that ZNF503-AS2 was mainly expressed in macrophages and tumor cells. Further analysis revealed that immunotherapy may have better efficacy in patients with low ZNF503-AS2 expression. In vitro experiments showed that knockdown of ZNF503-AS2 reduced the proliferation, invasion and migration ability of glioma cells, induced G2/M cell cycle arrest and promoted apoptosis.
ZNF503-AS2 might be a valuable biomarker for predicting the prognosis of glioma patients and a potential target for glioma therapy.</description><subject>Apoptosis</subject><subject>Biological effects</subject><subject>Biology and Life Sciences</subject><subject>Biomarkers</subject><subject>Biotechnology</subject><subject>Brain Neoplasms - genetics</subject><subject>Brain Neoplasms - immunology</subject><subject>Brain Neoplasms - pathology</subject><subject>Care and treatment</subject><subject>Cell cycle</subject><subject>Cell Line, Tumor</subject><subject>Cell Movement</subject><subject>Cell Proliferation</subject><subject>Complications and side effects</subject><subject>Development and progression</subject><subject>Diagnosis</subject><subject>Drug resistance</subject><subject>Female</subject><subject>Flow cytometry</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gene set enrichment analysis</subject><subject>Genes</subject><subject>Glioblastoma</subject><subject>Glioma</subject><subject>Glioma - genetics</subject><subject>Glioma - immunology</subject><subject>Glioma - metabolism</subject><subject>Glioma - pathology</subject><subject>Glioma cells</subject><subject>Gliomas</subject><subject>Growth factors</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Leukocyte migration</subject><subject>Macrophages</subject><subject>Male</subject><subject>Malignancy</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine and Health Sciences</subject><subject>Medicine, Experimental</subject><subject>Metastases</subject><subject>Microenvironments</subject><subject>MicroRNAs</subject><subject>Patient outcomes</subject><subject>Prognosis</subject><subject>Research and Analysis Methods</subject><subject>RNA, Long Noncoding - genetics</subject><subject>Therapeutic targets</subject><subject>Tissues</subject><subject>Transcriptomics</subject><subject>Tumor cells</subject><subject>Tumor Microenvironment - genetics</subject><subject>Tumor Microenvironment - immunology</subject><subject>Tumors</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptksFu1DAQhiMEoqXwBggsIVVcdhnHsWOfqlXVQqUKDsCFi-WN7axXib3YSRFvj9NNq11URXIs-5v5Z8Z_UbzFsMSkxp-2YYxedctd8GYJBFcM82fFKRakXLASyPOD_UnxKqUtACWcsZfFCRGsxEzQ08L9-npNgSxW30vkElJoF0PvkvMtGjYmqp0ZB9egQcXWDEh5fU-lFBqnBqPRHzdsJhK5vh-9Qb1rYjD-zsXge-MH5DxqOxd69bp4YVWXzJv5f1b8vL76cfllcfvt883l6nbRUKiGRSUsVFxoQjQrGVAl1gwA1rbGhGDgVhtGqxK4wnldq5JpS4U13CrBaW3JWfF-n3fXhSTnKSVJMKFAayirTNzsCR3UVu6i61X8K4Ny8v4gxFaqmLvujMSaMBAMsgSrcJbjQCtda93Ua9HYSe1iVhvXvdFNbjmq7ijp8Y13G9mGO4kxwxjTqZqPc4YYfo8mDTLPvzFdp7wJ41R4BaIkwCb0w3_o0-3NVKtyB87bkIWbKalcccwZx2XJM7V8gsqfNvkNs6esy-dHAecHARujumGTQpftEXw6Bqs9mJ2QUjT2cRoY5GTdh6rlZF05WzeHvTuc5GPQg1fJP6A76UA</recordid><startdate>20241202</startdate><enddate>20241202</enddate><creator>Wu, Yibo</creator><creator>Mu, Guangjing</creator><creator>Li, Fang</creator><creator>Sun, Yanfei</creator><creator>Lin, Xiaoying</creator><creator>Liu, Xuemeng</creator><creator>Zhao, Zhimin</creator><creator>Han, Mingzhi</creator><creator>Wang, Donghai</creator><creator>Huang, Bin</creator><creator>Li, Xingang</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0878-0211</orcidid><orcidid>https://orcid.org/0009-0008-6943-3396</orcidid><orcidid>https://orcid.org/0000-0002-0944-7648</orcidid></search><sort><creationdate>20241202</creationdate><title>ZNF503-AS2 is a promising therapeutic target and is associated with the immune microenvironment in glioma</title><author>Wu, Yibo ; Mu, Guangjing ; Li, Fang ; Sun, Yanfei ; Lin, Xiaoying ; Liu, Xuemeng ; Zhao, Zhimin ; Han, Mingzhi ; Wang, Donghai ; Huang, Bin ; Li, Xingang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-49f0489d33d62605a9b6000bf7133108fde654208a1420ba26df59fe8fa9857f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Apoptosis</topic><topic>Biological effects</topic><topic>Biology and Life Sciences</topic><topic>Biomarkers</topic><topic>Biotechnology</topic><topic>Brain Neoplasms - genetics</topic><topic>Brain Neoplasms - immunology</topic><topic>Brain Neoplasms - pathology</topic><topic>Care and treatment</topic><topic>Cell cycle</topic><topic>Cell Line, Tumor</topic><topic>Cell Movement</topic><topic>Cell Proliferation</topic><topic>Complications and side effects</topic><topic>Development and progression</topic><topic>Diagnosis</topic><topic>Drug resistance</topic><topic>Female</topic><topic>Flow cytometry</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gene set enrichment analysis</topic><topic>Genes</topic><topic>Glioblastoma</topic><topic>Glioma</topic><topic>Glioma - genetics</topic><topic>Glioma - immunology</topic><topic>Glioma - metabolism</topic><topic>Glioma - pathology</topic><topic>Glioma cells</topic><topic>Gliomas</topic><topic>Growth factors</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Leukocyte migration</topic><topic>Macrophages</topic><topic>Male</topic><topic>Malignancy</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine and Health Sciences</topic><topic>Medicine, Experimental</topic><topic>Metastases</topic><topic>Microenvironments</topic><topic>MicroRNAs</topic><topic>Patient outcomes</topic><topic>Prognosis</topic><topic>Research and Analysis Methods</topic><topic>RNA, Long Noncoding - genetics</topic><topic>Therapeutic targets</topic><topic>Tissues</topic><topic>Transcriptomics</topic><topic>Tumor cells</topic><topic>Tumor Microenvironment - genetics</topic><topic>Tumor Microenvironment - immunology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Yibo</creatorcontrib><creatorcontrib>Mu, Guangjing</creatorcontrib><creatorcontrib>Li, Fang</creatorcontrib><creatorcontrib>Sun, Yanfei</creatorcontrib><creatorcontrib>Lin, Xiaoying</creatorcontrib><creatorcontrib>Liu, Xuemeng</creatorcontrib><creatorcontrib>Zhao, Zhimin</creatorcontrib><creatorcontrib>Han, Mingzhi</creatorcontrib><creatorcontrib>Wang, Donghai</creatorcontrib><creatorcontrib>Huang, Bin</creatorcontrib><creatorcontrib>Li, Xingang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Yibo</au><au>Mu, Guangjing</au><au>Li, Fang</au><au>Sun, Yanfei</au><au>Lin, Xiaoying</au><au>Liu, Xuemeng</au><au>Zhao, Zhimin</au><au>Han, Mingzhi</au><au>Wang, Donghai</au><au>Huang, Bin</au><au>Li, Xingang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ZNF503-AS2 is a promising therapeutic target and is associated with the immune microenvironment in glioma</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2024-12-02</date><risdate>2024</risdate><volume>19</volume><issue>12</issue><spage>e0314618</spage><pages>e0314618-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Glioma is the most common intracranial malignancy, and the available treatment options are poor. Long noncoding RNAs (lncRNAs) have been reported to be involved in the malignant progression of glioma. The role of ZNF503-AS2 in glioma has not been reported.
We screened ZNF503-AS2 with upregulated expression in glioblastoma (GBM) by analyzing the TCGA, CGGA and GTEx databases. Single sample gene set enrichment analysis (ssGSEA) was used to calculate the enrichment of immune cells and signaling pathways in glioma samples. Single-cell datasets were used to analyze the distribution of ZNF503-AS2. In vitro experiments were used to investigate the biological function of ZNF503-AS2.
ZNF503-AS2 was highly expressed in glioma and was associated with poor prognosis, malignant progression and infiltration of immunosuppressive cells. Single-cell transcriptomic analysis showed that ZNF503-AS2 was mainly expressed in macrophages and tumor cells. Further analysis revealed that immunotherapy may have better efficacy in patients with low ZNF503-AS2 expression. In vitro experiments showed that knockdown of ZNF503-AS2 reduced the proliferation, invasion and migration ability of glioma cells, induced G2/M cell cycle arrest and promoted apoptosis.
ZNF503-AS2 might be a valuable biomarker for predicting the prognosis of glioma patients and a potential target for glioma therapy.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>39621695</pmid><doi>10.1371/journal.pone.0314618</doi><orcidid>https://orcid.org/0000-0002-0878-0211</orcidid><orcidid>https://orcid.org/0009-0008-6943-3396</orcidid><orcidid>https://orcid.org/0000-0002-0944-7648</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2024-12, Vol.19 (12), p.e0314618 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_3135057024 |
| source | Public Library of Science (PLoS) Journals Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Apoptosis Biological effects Biology and Life Sciences Biomarkers Biotechnology Brain Neoplasms - genetics Brain Neoplasms - immunology Brain Neoplasms - pathology Care and treatment Cell cycle Cell Line, Tumor Cell Movement Cell Proliferation Complications and side effects Development and progression Diagnosis Drug resistance Female Flow cytometry Gene Expression Regulation, Neoplastic Gene set enrichment analysis Genes Glioblastoma Glioma Glioma - genetics Glioma - immunology Glioma - metabolism Glioma - pathology Glioma cells Gliomas Growth factors Health aspects Humans Immune system Immunotherapy Leukocyte migration Macrophages Male Malignancy Medical prognosis Medical research Medicine and Health Sciences Medicine, Experimental Metastases Microenvironments MicroRNAs Patient outcomes Prognosis Research and Analysis Methods RNA, Long Noncoding - genetics Therapeutic targets Tissues Transcriptomics Tumor cells Tumor Microenvironment - genetics Tumor Microenvironment - immunology Tumors |
| title | ZNF503-AS2 is a promising therapeutic target and is associated with the immune microenvironment in glioma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T08%3A44%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ZNF503-AS2%20is%20a%20promising%20therapeutic%20target%20and%20is%20associated%20with%20the%20immune%20microenvironment%20in%20glioma&rft.jtitle=PloS%20one&rft.au=Wu,%20Yibo&rft.date=2024-12-02&rft.volume=19&rft.issue=12&rft.spage=e0314618&rft.pages=e0314618-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0314618&rft_dat=%3Cgale_plos_%3EA818681228%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3135057024&rft_id=info:pmid/39621695&rft_galeid=A818681228&rft_doaj_id=oai_doaj_org_article_1d360960f596410ba8054d7ddc7b9cff&rfr_iscdi=true |